Lyell Immunopharma Inc (LYEL)
1.51
-0.01
(-0.66%)
USD |
NASDAQ |
Sep 27, 16:00
1.505
0.00 (0.00%)
After-Hours: 20:00
Lyell Immunopharma Research and Development Expense (Annual): 182.94M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 182.94M |
| December 31, 2022 | 159.19M |
| December 31, 2021 | 138.69M |
| Date | Value |
|---|---|
| December 31, 2020 | 182.24M |
| December 31, 2019 | 63.60M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
63.60M
Minimum
2019
182.94M
Maximum
2023
145.33M
Average
159.19M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Ocular Therapeutix Inc | 61.06M |
| Marinus Pharmaceuticals Inc | 99.39M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |
| iBio Inc | 5.185M |